Mostrar el registro sencillo del ítem

The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorVERDOUX, Helene
IDREF: 115951903
dc.contributor.authorBITTNER, Robert A
dc.contributor.authorHASAN, Alkomiet
dc.contributor.authorQUBAD, Mishal
dc.contributor.authorWAGNER, Elias
dc.contributor.authorLEPETIT, Alexis
dc.contributor.authorARROJO-ROMERO, Manuel
dc.contributor.authorBACHMANN, Christian
dc.contributor.authorBEEX-OOSTERHUIS, Marieke
dc.contributor.authorBOGERS, Jan
dc.contributor.authorCELOFIGA, Andreja
dc.contributor.authorCOHEN, Dan
dc.contributor.authorDE BERARDIS, Domenico
dc.contributor.authorDE HERT, Marc
dc.contributor.authorDE LAS CUEVAS, Carlos
dc.contributor.authorEBDRUP, Bjørn H
dc.contributor.authorFOUNTOULAKIS, Konstantinos N
dc.contributor.authorGUINART, Daniel
dc.contributor.authorKEATING, Dolores
dc.contributor.authorKOPEČEK, Miloslav
dc.contributor.authorLALLY, John
dc.contributor.authorLAZÁRY, Judit
dc.contributor.authorLUYKX, Jurjen J
dc.contributor.authorMARONAS AMIGO, Olalla
dc.contributor.authorMOLDEN, Espen
dc.contributor.authorNIELSEN, Jimmi
dc.contributor.authorO'DONOGHUE, Brian
dc.contributor.authorOSWALD, Pierre
dc.contributor.authorRADULESCU, Flavian S
dc.contributor.authorROHDE, Christopher
dc.contributor.authorSAGUD, Marina
dc.contributor.authorSANZ, Emilio J
dc.contributor.authorŠIMUNOVIĆ FILIPČIĆ, Ivona
dc.contributor.authorSOMMER, Iris E
dc.contributor.authorTAIPALE, Heidi
dc.contributor.authorTIIHONEN, Jari
dc.contributor.authorTUPPURAINEN, Heli
dc.contributor.authorVEERMAN, Selene
dc.contributor.authorWILKOWSKA, Alina
dc.contributor.authorSPINA, Edoardo
dc.contributor.authorSCHULTE, Peter
dc.date.accessioned2025-04-07T07:18:07Z
dc.date.available2025-04-07T07:18:07Z
dc.date.issued2025-01-10
dc.identifier.issn1778-3585en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/205992
dc.description.abstractEnThe European Clozapine Task Force is a group of psychiatrists and pharmacologists practicing in 18 countries under European Medicines Agency (EMA) regulation, who are deeply concerned about the underuse of clozapine in European countries. Although clozapine is the most effective antipsychotic for people with treatment-resistant schizophrenia, a large proportion of them do not have access to this treatment. Concerns about clozapine-induced agranulocytosis and stringent blood monitoring rules are major barriers to clozapine prescribing and use. There is a growing body of evidence that the incidence of clozapine-induced agranulocytosis is very low after the first year of treatment. Maintaining lifelong monthly blood monitoring after this period contributes to unjustified discontinuation of clozapine. We leverage recent and replicated evidence on the long-term safety of clozapine to call for the revision and updating of the EMA's blood monitoring rules, thus aiming to overcome this major barrier to clozapine prescribing and use. We believe the time has come for relaxing the rules without increasing the risks for people using clozapine in Europe.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enClozapine
dc.subject.enHumans
dc.subject.enAntipsychotic Agents
dc.subject.enEurope
dc.subject.enAgranulocytosis
dc.subject.enDrug Monitoring
dc.subject.enAdvisory Committees
dc.subject.enSchizophrenia
dc.subject.enTreatment-Resistant
dc.title.enThe time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force
dc.title.alternativeEur Psychiatryen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1192/j.eurpsy.2024.1816en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39788917en_US
bordeaux.journalEuropean Psychiatryen_US
bordeaux.pagee17en_US
bordeaux.volume68en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-05022682
hal.version1
hal.date.transferred2025-04-07T07:18:14Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Psychiatry&rft.date=2025-01-10&rft.volume=68&rft.issue=1&rft.spage=e17&rft.epage=e17&rft.eissn=1778-3585&rft.issn=1778-3585&rft.au=VERDOUX,%20Helene&BITTNER,%20Robert%20A&HASAN,%20Alkomiet&QUBAD,%20Mishal&WAGNER,%20Elias&rft.genre=article


Archivos en el ítem

Thumbnail
Nombre:
BPH_EP_2025_Verdoux.pdf
Tamaño:
145.1Kb
Formato:
PDF
Ver/Abrir
Thumbnail
Nombre:
license_rdf
Tamaño:
914bytes
Formato:
application/rdf+xml
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem